Barclays’s DiaMedica Therapeutics DMAC Stock Holding History

Barclays’s Portfolio DMAC Stock Details DMAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$43.9K	Sell	6,487 -46,424	-88%	-$368K	﹤0.01%	4366
2025 Q4	$421K	Buy	52,911 +7,471	+16%	+$55.9K	﹤0.01%	3935
2025 Q3	$312K	Sell	45,440 -3,333	-7%	-$18.1K	﹤0.01%	4070
2025 Q2	$190K	Buy	48,773 +30,503	+167%	+$119K	﹤0.01%	4313
2025 Q1	$69.2K	Sell	18,270 -9,456	-34%	-$54.1K	﹤0.01%	4521
2024 Q4	$151K	Buy	+27,726	New	+$131K	﹤0.01%	4430
2021 Q4	–	Sell	-4,616	Closed	-$19K	–	4231
2021 Q3	$19K	Buy	4,616 +3,208	+228%	+$12.3K	﹤0.01%	4404
2021 Q2	$6K	Sell	1,408 -2,004	-59%	-$16.4K	﹤0.01%	4728
2021 Q1	$31K	Buy	+3,412	New	+$31.9K	﹤0.01%	4292

Other funds holding DMAC

CLG

Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PAPAIJV

Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Barclays's DMAC Position: Q1 2026 in Review

Barclays reduced its DiaMedica Therapeutics (DMAC) stake by 88% in Q1 2026, selling an estimated $368K and leaving 6,487 shares worth $43.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4366.

Barclays first reported a position in DMAC in Q1 2021 and has held it in 9 quarters since. The position peaked at $421K in Q4 2025. 99 funds tracked by Wall St. Rank hold DMAC as of Q1 2026.

Barclays held 6,487 shares of DiaMedica Therapeutics worth $43.9K as of Q1 2026.
Barclays sold 46,424 DiaMedica Therapeutics shares in Q1 2026, an estimated $368K.
DiaMedica Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4366 holding.
Barclays first reported a position in DiaMedica Therapeutics in Q1 2021 and has held it in 9 quarters since.
Barclays's DiaMedica Therapeutics position peaked at $421K in Q4 2025.
99 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.